- Dosing: Initiate at 300 mg orally per day and titrate up to 3600 mg per day in divided doses
- Extended-release formulations available
Titrate dose at initiation & taper upon discontinuation. Dose at bedtime.
- Relevant Off-Label Uses: neuropathy, hot flashes, acute post-operative pain, cancer pain
- Evidence: lacking specific to PMPS but has evidence for treating neuropathic pain and some coexisting conditions
- Relevant AEs: tolerability limited by dose-dependent adverse effects (e.g., dizziness, somnolence, peripheral edema, gait disturbance)
- Refer to DailyMed for full prescribing information...Watson (11-15) https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5969871e-6c71-4c37-9d63-370718ccc80c
- Moore RA, Wiffen PJ, Derry S, Rice ASC. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD007938. DOI: 10.1002/14651858.CD007938.pub3.
- NCCN Clinical Practice Guidelines in Oncology. Adult Cancer Pain. Version 2.2016.
Created by the NIH Center of Excellence in Pain Education at Southern Illinois University Edwardsville and Saint Louis University (Christopher Herndon, PharmD; Raymond Tait, PhD; McKenzie Ferguson, PharmD; Kimberly Levenhagen, PT, DPT, WCC; Rebecca Luebbert, PhD, RN; Gretchen Salsich, PhD, PT; Kevin Rowland, PhD; Kimberly Zoberi, MD). This project has been funded in whole or in part with Federal funds from the National Institutes of Health (NIH), Department of Health and Human Services, under Contract No. HHSN271201500056C. These materials are not in their final format. NIH is in the process of reviewing these materials.